Progress in Treatment of POEMS Syndrome--Review.
10.7534/j.issn.1009-2137.2018.04.047
- Author:
Wen-Jing FAN
1
;
Tao WU
2
;
Hai BAI
3
Author Information
1. Department of Hematology, Center for Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730050, Gansu Proince, China.The Second Clinical Medical College of Lanzhou University, Lanzhou 730030, Gansu Proince,China.
2. Department of Hematology, Center for Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730050, Gansu Proince, China.
3. Department of Hematology, Center for Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730050, Gansu Proince, China.E-mail: baihai98@tom.com.
- Publication Type:Journal Article
- MeSH:
Cytokine-Induced Killer Cells;
Humans;
Immunologic Factors;
POEMS Syndrome;
Stem Cell Transplantation;
Transplantation, Autologous
- From:
Journal of Experimental Hematology
2018;26(4):1225-1229
- CountryChina
- Language:Chinese
-
Abstract:
POEMS syndrome is a rare multiple organ involvement of the parasympathetic syndrome associated with abnormal plasma cells, mostly with high-dose chemotherapy and stem cell transplantation for the treatment. Recently, more treatment attempts to treat POEMS syndrome have been utilized so as to improve the efficacy and safety for the patients with POEMS syndrome, such as immunomodulator, alkylating agent, cytokine-induced killer cells and so on. Lenalidomide has a significant effect on relapse/refractory POEMS syndrome and patients with endocrinopathy. Cytokine-induced killer cells are also a safe and effective regimen for the treatment of POEMS syndrome. This review described the efficacy and safety of immunomodulatos, alkylators, cytokine-induced killer cells, ASCT, proteasome inhibitors and monoclonal antibodies for POEMS syndrome, and the newest clinical research and progress of POEMS syndrome ware summarized briefly.
